CNP-104, an Antigen-Specific Tolerogenic Nanoparticle Therapy, Stabilizes Prognostic Trajectory and Liver Stiffness with a Link to Reduction in Pathogenic T-Cells in Primary Biliary Cholangitis

Christopher Bowlus – University of California Davis; Molly Frey – COUR Pharma; Derrick McCarthy – COUR Pharma; Erik Wambre – Precision Immunology Institute; Stephen Caldwell – University of Virginia; Roberto Firpi-Morell – University of Florida; Brett Fortune – Montefiore Medical Center; Michael Galambos – Digestive Healthcare of Georgia; Stuart Gordon – Henry Ford Health; Denise Harnois – Mayo Clinic Florida; Tarek Hassanein – Southern California Research Center; Matthew Kappus – Duke University School of Medicine; Eric Lawitz – Texas Liver Institute; Scott McHenry – Washington University School of Medicine in St. Louis; Bhaktasharan Patel – Peak Gastroenterology Associates; Raymond Phillips – GI Pros Research; Daniel Pratt – Massachusetts General Hospital; Jatinder Pruthi – Om Research; Govarthanan Rajendiran – Sanford Medical Center; Gautham Reddy – University of Chicago; Manuel Rodriguez – Florida Research Institute; Marina Silveira – Yale School of Medicine; Bobby Zervos – Cleveland Clinic Weston Hospital; M Eric Gershwin – University of California Davis; Paul Peloso – COUR Pharma